Ultomiris Drug Market: Transforming the Landscape of Rare Disease Treatment Ultomiris (ravulizAdd Newumab), developed by Alexion Pharmaceuticals and acquired by AstraZeneca in 2021, has emerged as a groundbreaking treatment for rare, complement-mediated disorders. As a long-acting monoclonal antibody, Ultomiris offers patients extended dosing intervals, enhancing convenience and adherence....